Rxsight, INC Schedule 13G passive stakes

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported beneficial ownership of 7.3% of RxSight, Inc. common stock.

The Vanguard Group filed an amended Schedule 13G for RxSight Inc, reporting 0% beneficial ownership due to an internal reporting realignment.

Artisan Partners Asset Management Inc. and its affiliates have reported a 5.2% passive beneficial ownership stake in RxSIGHT, Inc. common stock.

RA Capital Management and its affiliates have reported a 0.0% beneficial ownership in RxSight, Inc., indicating a full divestment of their previous holdings.

Artisan Partners Asset Management Inc. and its affiliates have filed an amended Schedule 13G, disclosing a reduced beneficial ownership of 4.3% in RxSIGHT, INC. common stock.

Millennium Management LLC and its affiliates have reported a 5.4% beneficial ownership stake in RxSight, Inc., holding 2,193,062 shares of common stock.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 5.8% beneficial ownership stake in RxSight, Inc. as of September 30, 2025.

Divisadero Street Capital Management and related entities disclose a 0.5% beneficial ownership stake in RxSight, Inc. common stock.

Bank of America Corporation and its subsidiaries reported a 0.4% beneficial ownership stake in RxSight, Inc. common stock as of June 30, 2025.

Artisan Partners Asset Management Inc. and its affiliates have disclosed a 5.5% beneficial ownership stake in RxSIGHT, INC. common stock.

Millennium Management LLC, along with its affiliates, has reported a 6.4% beneficial ownership stake in RxSight, Inc., holding 2,610,977 shares of common stock.

Divisadero Street Capital Management, LP and its affiliates have reported a beneficial ownership of 6.3% in RxSight, Inc., signaling a notable institutional investment in the medical technology company.

Bank of America Corporation and its subsidiaries have reported a passive beneficial ownership of 5.4% in RxSight, Inc., totaling 2,181,788 shares of common stock as of December 31, 2024.

Investment adviser Lord, Abbett & Co. LLC has filed an Amendment No. 1 to its Schedule 13G, reporting a significant reduction in its beneficial ownership of RxSIGHT, Inc. common stock, now standing at 0.00% as of December 31, 2024.